Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Japan, US, Europe Anti-Infective Agent Markets Grow 48.4% in FY2014 Driven by Anti-HCV Treatments: Survey
July 7, 2015
- Foreign Drug Makers’ Sales Dip on Generic Inroads in 2014
July 6, 2015
- Multiple Myeloma Treatment Farydak Approved: Novartis
July 6, 2015
- Once-Weekly GLP-1 Receptor Agonist Trulicity Approved: Eli Lilly Japan
July 6, 2015
- Idiopathic Pulmonary Fibrosis Treatment OFEV Approved: NBI
July 6, 2015
- Immune Checkpoint Inhibitor Yervoy Approved for Malignant Melanoma: Bristol-Myers
July 6, 2015
- Lupus Erythematosus Treatment Plaquenil Approved: Sanofi
July 6, 2015
- Hepatitis C Treatment Harvoni Approved: Gilead Sciences
July 6, 2015
- MTPC Preparing to Submit Radicut for an Indication of ALS in the US
July 3, 2015
- Santen Files IND Application for Anti-Endoglin Antibody for Wet AMD in US
July 3, 2015
- President Tada to Double as Drug Development Head: Sumitomo Dainippon
July 3, 2015
- JCR Aims at Growth through New Products, Out-Licensing Activities
July 2, 2015
- Merck Serono, Nippon Shinyaku to Copromote Gonalef
July 2, 2015
- Announcement: 2nd Annual Oncology Asia - Sheraton Miyako Hotel Tokyo, September 7-9
July 2, 2015
- Bayer Files for Regulatory Approval of Hemophilia A Treatment in Japan
July 1, 2015
- Daiichi Sankyo Acquires Additional Shares in Kitasato Daiichi Sankyo Vaccine for 10 Billion Yen
July 1, 2015
- Febuxostat Approved for Hyperuricemia Associated with Cancer Chemotherapy in Europe: Teijin Pharma
July 1, 2015
- Taisho, Ablynx of Belgium to Collaborate for Development and Commercialization of Anti-TNF-α Nanobody
July 1, 2015
- Otsuka Initiates Voluntary Recall of Uniphyl
June 30, 2015
- Takecab Slips to 2nd Place as Suglat Comes 1st in GP Market in May: Anterio Ranking
June 30, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…